There is an interesting article in the current issue of The Journal of Precision Medicine on Alzheimer's. The article attempts to answer a seemingly simple, yet complex question...Can systems biology…
At last month's Biotech Showcase, a panel discussion was held discussing different models for advancing assets without resorting to a license. The link to the discussion is here. It…
Nearly 30 years ago, back when your author was a humble pharmacy intern, the first therapeutic to combat HIV (azidothymidine) was introduced by Burroughs Wellcome (now part of GSK). Back…
Given that we are now in January, we feel obliged to craft some sort of "Predictions for 2016" post. We're not big fans of predictive posts, mainly because we're…
I love what you did with the place... It's always difficult for us to contribute any sensible overarching overview of any partnering conference, especially BIO Europe Fall. This is entirely…
Last month, EBD and IMS partnered to analyze meeting outcomes from four conferences, covering nearly 5,000 participating companies. Their report is available here (PDF). As we are knee-deep in scheduling…
Michael Gilman, CEO of Padlock Therapeutics, wrote a terrific post recounting his experiences from in-licensing assets from Big Pharma. Mike's perspective is unique in that he has managed to…
The July/August issue of Drug Development and Delivery has an extensive report on the business and science of formulation and drug delivery. The report is based on the data…
This question came up recently when I was describing one of our current clients as a "good" client. But what exactly is a "good" client? Three things come to…
What follows is a true story. In 2013, we were engaged to out-license a series of Preclinical assets. One of these assets was in a therapeutic area which had very few…